, ,

Positive data with vamorolone in DMD

Santhera Announces Presentation by ReveraGen of Positive 18-Month Data with Vamorolone in Duchenne Muscular Dystrophy   La Force is happy to share this press release provided by Santhera Pharmaceuticals, October 7, 2019, > PRESS RELEASE <   Santhera Pharmaceuticals announces the presentation of data showing continued improvement of muscle function and improved tolerability compared with corticosteroids […]

Translarna™ (ataluren) Slows Disease Progression in Patients with DMD

PTC Therapeutics announces new real-world analysis demonstrating Translarna™ (ataluren) slows disease progression in patients with Duchenne muscular dystrophy   La Force is happy to share this press release provided by PTC Therapeutics, Inc.  Oct 4, 2019  > PRESS RELEASE < Lung function data from the STRIDE Registry show a trend toward delay of the decline […]

, ,

PolarisDMD Trial in DMD has exceeded target enrollment

Phase 3, PolarisDMD trial of edasalonexent in DMD has exceeded target enrollment   La Force is happy to share the latest edition of the Catabasis Connection newsletter   Catabasis Pharmaceuticals, Inc. announced today the completion of enrollment for the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD). The target enrollment of 125 boys […]

, ,

Sarepta Therapeutics receives Complete Response Letter for golodirsen

Sarepta Therapeutics receives Complete Response Letter from the US Food and Drug Administration for golodirsen New Drug Application Sarepta Therapeutics, Inc announced it had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) seeking accelerated approval of golodirsen injection for the treatment of Duchenne […]

,

All PolarisDMD sites are now launched

Catabasis announces that all 40 sites, across eight countries, are now fully launched for the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy! La Force is happy to share the latest edition of the Catabasis Connection newsletter about the Phase 3 PolarisDMD trial for edasalonexent in Duchenne. The Phase 3 PolarisDMD trial is […]

Survey for Canadian families living with Duchenne Muscular Dystrophy

Dear Duchenne Family,  On behalf of Stand for Duchenne Canada, Jesse’s Journey and La Force DMD, thank you for your interest in participating in this survey for Canadian families living with Duchenne Muscular Dystrophy (DMD).   The purpose of this survey is to gather vital information to submit to Health Canada, describing the impact Duchenne […]